The medical bottles and the syringe are seen with the Novo Nordisk brand proven on the again display screen.
Nurphoto | Nurphoto | Ghetto photographs
Shares on Novo nordisk It fell Monday after the Danish pharmaceutical big stated the following technology weight reduction drug helped overweight or obese grownup sufferers with kind 2 diabetes drops 15.7% of their weight after 68 weeks.
The corporate’s shares dropped by 6.3% at 11:22 pm London time.
Novo Nordisk, which produces the fiercely fashionable weight reduction medication, Wegovy, forecast Weight lack of 25% for sufferers taking caagrisema. In one other late expertise, printed in December, the corporate discovered that Cagrisema helped sufferers drop some weight by 22.7% on this check.
Cagrisema is examined by Novo Nordisk as a weight reduction medication for adults who’re obese or overweight, in addition to the therapy of adults with kind 2 diabetes. Presently, the corporate expects to use for regulatory approval for Cagrisema within the first quarter of 2026.
Shares from the American competitor Eli LilyWho makes the medication for weight reduction Mounjaro briefly jumped greater after Novo Nordisk’s replace on Monday, however was traded by 1.2% to 11:34 in London.
Markets hope that Cagricema can become a next -generation weight loss medicineS Therapy, injected as soon as per week, is a mixture of cagrilintide and semi -glutide – the energetic ingredient in Vegovi.
The Cagrisema Part 3 check had 1 206 members with a mean base physique weight of 102 kg (225 kilos).
Regardless of the adverse response of traders outcomes on Monday, Novo Nordisk advertises the “superior weight reduction” achieved by those that take Cagricema in comparison with those that have obtained placebo, which threw solely 3.1% of their weight all through the 68 weeks.
Novo Nordisk additionally stated that the drug appears to have a “secure and well-tolerated profile”, the commonest aspect impact being delicate to reasonable gastrointestinal signs. They decreased over time.
Last weekNovo Nordisk launched a web based pharmacy, Novocare, to permit customers to purchase Wegovy immediately from the corporate at a decreased value of $ 499 a month.
The success of medicines for weight reduction Wegovy and Ozepic helped Novo Nordisk to develop into One of the most precious companies in the worldS
